Comparative Pharmacology
Head-to-head clinical analysis: NUBAIN versus OPANA ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUBAIN versus OPANA ER.
NUBAIN vs OPANA ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nalbuphine is a mixed opioid agonist-antagonist. It acts as an agonist at kappa opioid receptors and as an antagonist at mu opioid receptors, providing analgesia with a ceiling effect for respiratory depression.
Opana ER (oxymorphone hydrochloride) is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action is analgesia via activation of mu-opioid receptors in the central nervous system, leading to altered perception and response to pain.
10-20 mg IV, IM, or SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum daily dose 160 mg.
Initial: 5 mg orally every 12 hours; titrate by 5-10 mg every 12 hours every 3-7 days; maximum 40 mg every 12 hours.
None Documented
None Documented
3.5–5 hours (terminal elimination half-life); clinically, in hepatic or renal impairment, half-life may be prolonged, requiring dose adjustment.
Terminal elimination half-life: 11.1–13.8 hours; clinically relevant as steady-state achieved in 2–3 days
Primarily renal (83% as unchanged drug and glucuronide conjugate); fecal excretion accounts for <5%.
Renal (primarily as glucuronide conjugates and unchanged drug): 85-90%; Fecal: <10%
Category C
Category C
Opioid Analgesic
Opioid Analgesic